The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices
Open accessAbstract
More than 2 million people worldwide are being treated for end-stage kidney disease (ESKD). This Series paper provides an overview of incidence, modality use (in-centre haemodialysis, home dialysis, or transplantation), and mortality for patients with ESKD based on national registry data. We also present data from an international cohort study to highlight differences in haemodialysis practices that affect survival and the experience of patients who rely on this therapy, which is both life-sustaining and profoundly disruptive to their quality of life. Data illustrate disparities in access to renal replacement therapy of any kind and in the use of transplantation or home dialysis, both of which are widely considered preferable to in-centre haemodialysis for many patients with ESKD in settings where infrastructure permits. For most patients with ESKD worldwide who are treated with in-centre haemodialysis, overall survival is poor, but longer in some Asian countries than elsewhere in the world, and longer in Europe than in the USA, although this gap has reduced. Commendable haemodialysis practice includes exceptionally high use of surgical vascular access in Japan and in some European countries, and the use of longer or more frequent dialysis sessions in some countries, allowing for more effective volume management. Mortality is especially high soon after ESKD onset, and improved preparation for ESKD is needed including alignment of decision making with the wishes of patients and families.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Worldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans
Genovese, G., Friedman, D. J., Ross, M. D., Lecordier, L., Uzureau, P., Freedman, B. I., Bowden, D. W., Langefeld, C. D., Oleksyk, T. K., Uscinski Knob, A. L., et al. (2010) · Science · doi:10.1126/science.1193032 · Cited by 2,028
Sehulster, L. M., & Chinn, R. Y. W. (2003) · PubMed · Cited by 1,457
Owen, W. F., Lew, N. L., Liu, Y., Lowrie, E. G., & Lazarus, J. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291404 · Cited by 1,404
KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update
Daugirdas, J. T., Depner, T. A., Inrig, J., Mehrotra, R., Rocco, M. V., Suri, R. S., Weiner, D. E., Greer, N., Ishani, A., MacDonald, R., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.07.015 · Cited by 1,320
Tentori, F., Blayney, M. J., Albert, J. M., Gillespie, B. W., Kerr, P. G., Bommer, J., Young, E. W., Akizawa, T., Akiba, T., Pisoni, R. L., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.03.020 · Cited by 1,075
Self-citationIn-Center Hemodialysis Six Times per Week versus Three Times per Week
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001593 · Cited by 1,008
Cardiovascular Disease and Risk Factors in Asia: A Selected Review
Ueshima, H., Sekikawa, A., Miura, K., Turin, T. C., Takashima, N., Kita, Y., Watanabe, M., Kadota, A., Okuda, N., Kadowaki, T., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.790048 · Cited by 919
Mapes, D. L., Lopes, A. A., Satayathum, S., Mccullough, K. P., Goodkin, D. A., Locatelli, F., Fukuhara, S., Young, E. W., Kurokawa, K., Saito, A., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00072.x · Cited by 858
Cited by
Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy
Thurlow, J. S., Joshi, M., Yan, G., Norris, K. C., Agodoa, L. Y., Yuan, C. M., & Nee, R. (2021) · American Journal of Nephrology · doi:10.1159/000514550 · Cited by 855
The current and future landscape of dialysis
Himmelfarb, J., Vanholder, R., Mehrotra, R., & Tonelli, M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0315-4 · Cited by 650
Chan, C. T., Blankestijn, P. J., Dember, L. M., Gallieni, M., Harris, D. C. H., Lok, C. E., Mehrotra, R., Stevens, P. E., Wang, A. Y.-M., Cheung, M., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.01.017 · Cited by 427
Self-citation
Metadata
- Authors
- Robinson, B. M., Akizawa, T., Jager, K. J., Kerr, P. G., Saran, R., & Pisoni, R. L.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 388
- Issue
- 10041
- Pages
- 294-306
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2406351639
- Cited by
- 415
- References
- 87
- FWCI
- 29.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. https://app.cochat.ai/papers/10.1016/s0140-6736(16)30448-2
- The paper
- Robinson, B. M., Akizawa, T., Jager, K. J., Kerr, P. G., Saran, R., & Pisoni, R. L. (2016). Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. The Lancet. https://doi.org/10.1016/s0140-6736(16)30448-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.